Atrial Fibrillation - Drug Pipeline Landscape, 2023
Description
Atrial Fibrillation - Drug Pipeline Landscape, 2023
Atrial fibrillation is a type of cardiac arrhythmia acclaimed by an anomalous cardiac rhythm element by a disturbance in heart’s electrical system. There are three types of atrial fibrillation Paroxysmal atrial fibrillation, Persistent atrial fibrillation, Long-standing persistent atrial fibrillation.
Causes of atrial fibrillation are augmentation of blood clots within the upper chambers of the heart and age, heart disease, high blood pressure, family history and drinking alcohol.
Symptoms include decreased blood pressure, weakness, lightheadedness, confusion and chest pain.
Atrial fibrillation is diagnosed by electrocardiogram (ECG or EKG), blood tests, holter monitor, chest X-ray.
Atrial fibrillation is treated by lifestyle changes and drugs like potassium channel blockers, beta-blockers and calcium channel blockers.
There are many clinical trials currently ongoing in atrial fibrillation drug development. Some of the most promising trials are studying new ways to prevent or treat atrial fibrillation, including new drugs, devices, and surgical procedures. Many of these trials are still in the early stages, but they offer hope for better treatments for this common and potentially deadly condition.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the treatment of Atrial Fibrillation treatment such as Xeomin, Abelacimab, HSY244, and others. Key players involved in the development of therapies to treat Atrial Fibrillation are AbbVie Inc, Bayer, Novartis, and others. Two drugs are under Phase III clinical trials and 10+ drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development.
Report Highlights
Global Insight Service’s, Atrial Fibrillation - Drug Pipeline Landscape, 2023 report provides an overview of the Atrial Fibrillation pipeline drugs. This report covers detailed insights on Atrial Fibrillation drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Atrial Fibrillation pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Atrial fibrillation is a type of cardiac arrhythmia acclaimed by an anomalous cardiac rhythm element by a disturbance in heart’s electrical system. There are three types of atrial fibrillation Paroxysmal atrial fibrillation, Persistent atrial fibrillation, Long-standing persistent atrial fibrillation.
Causes of atrial fibrillation are augmentation of blood clots within the upper chambers of the heart and age, heart disease, high blood pressure, family history and drinking alcohol.
Symptoms include decreased blood pressure, weakness, lightheadedness, confusion and chest pain.
Atrial fibrillation is diagnosed by electrocardiogram (ECG or EKG), blood tests, holter monitor, chest X-ray.
Atrial fibrillation is treated by lifestyle changes and drugs like potassium channel blockers, beta-blockers and calcium channel blockers.
There are many clinical trials currently ongoing in atrial fibrillation drug development. Some of the most promising trials are studying new ways to prevent or treat atrial fibrillation, including new drugs, devices, and surgical procedures. Many of these trials are still in the early stages, but they offer hope for better treatments for this common and potentially deadly condition.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the treatment of Atrial Fibrillation treatment such as Xeomin, Abelacimab, HSY244, and others. Key players involved in the development of therapies to treat Atrial Fibrillation are AbbVie Inc, Bayer, Novartis, and others. Two drugs are under Phase III clinical trials and 10+ drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development.
Report Highlights
Global Insight Service’s, Atrial Fibrillation - Drug Pipeline Landscape, 2023 report provides an overview of the Atrial Fibrillation pipeline drugs. This report covers detailed insights on Atrial Fibrillation drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Atrial Fibrillation pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Table of Contents
95 Pages
- 1. Introduction
- 1.1 Atrial Fibrillation – Pipeline Drugs, 2023-Coverage
- 2. Disease Overview – Atrial Fibrillation
- 2.1 Causes
- 2.2 Signs and Symptoms
- 2.3 Diagnosis
- 2.4 Disease Management
- 3. Atrial Fibrillation – Pipeline Drugs Development - Overview
- 3.1 Comparative Analysis by Stage of Development
- 3.2 Number of Products under Development by Companies, 2023
- 3.3 Products under Development by Companies, 2023
- 4. Assessment of Therapeutics
- 4.1 Assessment by Target
- 4.2 Assessment by Mechanism of Action
- 4.3 Assessment by Molecule Type
- 4.4 Assessment by Route of Administration
- 5. Drug Profiles
- 5.1 Clinical Stage Drugs – Phase III
- 5.1.1 FlecIH-103
- 5.1.2 Xeomin
- 5.2 Clinical Stage Drugs – Phase II
- 5.2.1 Abelacimab
- 5.2.2 AGN-151607
- 5.2.3 AP30663
- 5.2.4 BAY2433334
- 5.2.5 Etripamil
- 5.2.6 Gencaro
- 5.2.7 HBI-3000
- 5.2.8 HSY244
- 5.2.9 K201
- 5.2.10 M201-A
- 5.2.11 OMT-28
- 5.3 Clinical Stage Drugs – Phase I
- 5.3.1 HIP2001
- 5.4 Clinical Stage Drugs – Preclinical
- 5.4.1 Carbachol
- 5.4.2 CKD-510
- 5.4.3 CTP - Amio
- 5.4.4 Dofetilide
- 5.4.5 Drug for Atrial Fibrillation
- 5.4.6 Drug for persistant Atrial Fibrillation
- 5.4.7 Gene Therapy
- 6. Key Regulatory Designations
- 7. Key Deals
- 8. Key Upcoming Milestones
- 9. Key Companies Involved
- 9.1 AbbVie
- 9.2 Acesion Pharma
- 9.3 Aetas Pharma Co Ltd
- 9.4 Anabios Corporation
- 9.5 Anthos Therapeutics Inc
- 9.6 ARCA Biopharma Inc
- 9.7 Bayer AG
- 9.8 Chong Kun Dang Pharmaceutical
- 9.9 Hanmi Pharmaceutical Company Limited
- 9.10 Huyabio International LLC
- 9.11 Hyloris Pharmaceuticals
- 9.12 InCarda Therapeutics Inc
- 9.13 Inomagen Therapeutics Inc
- 9.14 Merz Pharmaceuticals
- 9.15 Milestone Pharmaceuticals Inc
- 9.16 Novartis Pharmaceuticals
- 9.17 Omeicos Therapeutics GmbH
- 9.18 Vivasc Therapeutics
- 10. Dormant Drugs
- 10.1 Inactive Drugs
- 10.2 Discontinued Drugs
- 11. Appendix
- List of Tables
- Table 1. 2 Number of Products under Development by Companies
- Table 1. 3 Products under Development by Companies
- Table 1. 4 Products by Targets
- Table 1. 5 Products by Mechanism of Action
- Table 1. 6 Products by Molecule Type
- Table 1. 7 Products by Route of Administration
- Table 2. 1 Clinical Trial Details - Xeomin/Merz Pharmaceuticals
- Table 2. 2 Clinical Trial Details - Abelacimab/Anthos Therapeutics Inc
- Table 2. 3 Clinical Trial Details - Gencaro/ARCA Biopharma Inc
- Table 2. 4 Clinical Trial Details - FlecIH-103 /InCarda Therapeutics Inc
- Table 2. 5 Clinical Trial Details - HSY244/Novartis Pharmaceuticals
- Table 2. 6 Clinical Trial Details - OMT-28/Omeicos Therapeutics GmbH
- Table 2. 7 Clinical Trial Details - HBI-3000/Huyabio International LLC
- Table 2. 8 Clinical Trial Details - AP30663/Acesion Pharma
- Table 2. 9 Clinical Trial Details - BAY2433334/Bayer
- Table 2. 10 Clinical Trial Details - AGN-151607/AbbVie
- Table 2. 11 Clinical Trial Details - M201-A/Aetas Pharma Co Ltd
- Table 2. 12 Clinical Trial Details - HIP2001/Hanmi Pharmaceutical Company Limited
- Table 2. 13 Clinical Trial Details - Etripamil/Milestone Pharmaceuticals Inc
- Table 3. 1 Regulatory Designations
- Table 4. 1 Inactive Drugs
- Table 4.2 Discontinued Drugs
- List of Figures
- Figure 1. 1 Number of Products under Development for Atrial Fibrillation, 2023
- Figure 1. 2 Products by Top 5 Targets and Stage of Development for Atrial Fibrillation, 2023
- Figure 1. 3 Products by Top 5 Mechanism of Action for Atrial Fibrillation, 2023
- Figure 1. 4 Products by Top 5 Molecule Type for Atrial Fibrillation, 2023
- Figure 1. 5 Products by Top 5 Route of Administration for Atrial Fibrillation, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
